MedTrace Logo

Cholesterol Reduction in Seniors Program (CRISP)

NCT00000477 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-02-18

No results posted yet for this study

Summary

To conduct a pilot study to determine whether lowering elevated serum cholesterol levels with 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase inhibitors reduced mortality due to the sequelae of atherosclerotic cardiovascular disease in older men and women.

Conditions

Interventions

DRUG

lovastatin

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • William Applegate · University of Tennessee

  • John Crouse · Bowman Gray School of Medicine

  • Donald Hunninghake · University of Minnesota

  • Robert Knopp · University of Washington

  • John LaRosa · George Washington University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION

Eligibility

Min Age
65 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1990-07-31
Completion
1992-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000477 on ClinicalTrials.gov